Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Desonide
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alembic Pharmaceuticals Receives USFDA Final Approval for Desonide Cream, 0.05%
Details : Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of inflammatory and Pruritic manifestations of corticosteroid-responsive dermatoses.
Brand Name : Desonide-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 09, 2022
Lead Product(s) : Desonide
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?